Adlai Nortye Ltd.
- ANL
- NASDAQ
- Biotechnology
- Clinical-Stage Biotech (Oncology)
- Kinase Inhibitors (PI3K)
$11.03
Today −8.77%Quote Oct 16, 2026, 08:00 PM UTC
−27.81%over the last month
Max drawdown −34.5%From 1-month high −33.6%3 months −7.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$175.6M
Approximate share count
Next earnings
Mar 3
Expected, not confirmed
Analyst target
$33.00
+199.2% from here
Floor
—
Data unavailable
Where the price sits
1 analyst
Analyst range, low to high
$20.00$49.00
- Price $11.03
- Resistance $11.06
- Consensus $33.00
The price is right under resistance. Analysts' average target sits about 199% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ANLPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
109